ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 360 filers reported holding ROYALTY PHARMA PLC in Q4 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,703,502 | -12.5% | 64,600 | +0.8% | 0.02% | -13.0% |
Q1 2024 | $1,946,717 | +7.9% | 64,100 | -0.2% | 0.02% | 0.0% |
Q4 2023 | $1,803,378 | +4.1% | 64,200 | +0.6% | 0.02% | -8.0% |
Q3 2023 | $1,731,532 | -11.4% | 63,800 | +0.3% | 0.02% | -7.4% |
Q2 2023 | $1,955,064 | -18.2% | 63,600 | -4.1% | 0.03% | -22.9% |
Q1 2023 | $2,388,789 | -8.8% | 66,300 | 0.0% | 0.04% | -16.7% |
Q4 2022 | $2,620,176 | -0.7% | 66,300 | +0.9% | 0.04% | -4.5% |
Q3 2022 | $2,639,000 | -4.1% | 65,700 | +0.3% | 0.04% | 0.0% |
Q2 2022 | $2,753,000 | +21.9% | 65,500 | +12.9% | 0.04% | +46.7% |
Q1 2022 | $2,259,000 | -3.9% | 58,000 | -1.7% | 0.03% | +3.4% |
Q4 2021 | $2,351,000 | +10.6% | 59,000 | +0.3% | 0.03% | 0.0% |
Q3 2021 | $2,125,000 | -15.8% | 58,800 | -4.5% | 0.03% | -12.1% |
Q2 2021 | $2,525,000 | -5.7% | 61,600 | +0.3% | 0.03% | -10.8% |
Q1 2021 | $2,678,000 | +153.6% | 61,400 | +191.0% | 0.04% | +146.7% |
Q4 2020 | $1,056,000 | – | 21,100 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
Brown University | 621,759 | $24,224,000 | 5.93% |
Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |